Oramed Pharmaceuticals Inc.

ORMP

As of the close on Sep 25, 2026

Price

$4.73

Market cap

$197M

P/E (diluted TTM)

1.1

EPS (TTM)

$4.13

Four quarters to Jun 30, 2026

Dividend yield

—

Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Oramed Pharmaceuticals Inc. Makes Money

Follow each dollar of revenue through to what shareholders keep.

From revenue to net income

Pick a year or quarter. Each band's width is its dollar amount.

Source: Oramed Pharmaceuticals Inc. — 10-Q filed May 19, 2026

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 13 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Mar 31, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Unusually large insider trades

Each trade is compared with the other insider trades of the same kind in the same security among Oramed Pharmaceuticals Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.

2023-03-14 · KIDRON NADAV: Larger than all 15 other insider purchases of Common Stock on file. SEC filing
2023-03-14 · Rozov Yadin: Larger than 14 of the 15 other insider purchases of Common Stock on file. SEC filing

Independent insiders buying near the same time

2023-03-13–2023-03-16: 4 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing )

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2023-04-04	Mayer Arie · Director	Common Stock	P — Open market or private purchase	+3,800	2.21	SEC filing
2023-04-03	Mayer Arie · Director	Common Stock	P — Open market or private purchase	+5,009	2.22	SEC filing
2023-03-16	KIDRON NADAV · President and CEO	Common Stock	P — Open market or private purchase	+26,000	2.04	SEC filing
2023-03-14	Rozov Yadin · Director	Common Stock	P — Open market or private purchase	+50,000	2.05	SEC filing
2023-03-14	KIDRON NADAV · President and CEO	Common Stock	P — Open market or private purchase	+100,000	2.01	SEC filing
2023-03-14	Kidron Miriam · Chief Scientific Officer	Common Stock	S — Open market or private sale	−100,000	2.01	SEC filing
2023-03-13	Rozov Yadin · Director	Common Stock	P — Open market or private purchase	+20,000	1.96	SEC filing
2023-01-03	Rabinowitz Michael · Chief Commercial Officer	Common Stock	S — Open market or private sale	−1,425	13.01	SEC filing

Showing 8 of 19 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-03-30	Kidron Miriam · Chief Scientific Officer	Common Stock	F — Payment of exercise price or tax by delivering securities	−435,084	SEC filing
2026-03-30	KIDRON NADAV · President and CEO	Common Stock	F — Payment of exercise price or tax by delivering securities	−44,818	SEC filing
2026-03-17	Hexter Joshua · COO & CBO	Common Stock	A — Grant, award, or other acquisition	+95,889	SEC filing
2026-03-17	Kidron Miriam · Chief Scientific Officer	Common Stock	A — Grant, award, or other acquisition	+119,558	SEC filing
2026-03-17	Gabay Avraham · Chief Financial Officer	Common Stock	A — Grant, award, or other acquisition	+95,889	SEC filing
2026-03-17	KIDRON NADAV · President and CEO	Common Stock	A — Grant, award, or other acquisition	+167,005	SEC filing
2026-03-12	KIDRON NADAV · President and CEO	Common Stock	G — Bona fide gift	−100,000	SEC filing
2026-01-22	Gabay Avraham · Chief Financial Officer	Common Stock	M — Exercise or conversion of derivative security	+19,000	SEC filing

Showing 8 of 40 rows

Other activity

		Security	Code		Filing
2021-02-26	Sank Leonard · Director	Common Stock	J — Other acquisition or disposition	−78,125	SEC filing
2021-02-26	Sank Leonard · Director	Common Stock	J — Other acquisition or disposition	−375,000	SEC filing
2019-06-17	Gabay Avraham · CFO, Treasurer and Secretary	Stock Option (right to buy)	D — Disposition to the issuer	−33,146	SEC filing
2019-04-10	RAKIN KEVIN · Director	Stock Option (right to buy)	D — Disposition to the issuer	−10,000	SEC filing
2019-02-26	Kidron Miriam · Chief Scientific Officer	Stock Option (right to buy)	D — Disposition to the issuer	−104,000	SEC filing
2019-02-26	KIDRON NADAV · President and CEO	Stock Option (right to buy)	D — Disposition to the issuer	−196,500	SEC filing

Showing 6 of 6 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.